Aim. Studies on the murine B16 melanoma animal model have shown that solid tumor formation was not observed with the simultaneous administration of melanoma cells and complexes of oligoribonucleotides with D-mannitol (ORNs-D-m). The aim of this work was to study the effect of ORNs-D-m and similar compounds on the viability of different tumor cell lines.
Materials and methods. Murine B16 melanoma and human U251 glioblastoma were investigated. Oligoribonucleotides (ORNs), ORNs-D-m (both in the acid form), and their sodium salts were applied for the treatment. The growth inhibition of tumor cells was assessed with methyl thiazolyl tetrazolium (MTT). A comparison of the effect of compounds was carried out by the concentration of half-maximal inhibition of IC50.
Results. The duration and dose of ORNs-D-m treatment effects on B16 viability. Thus, the IC50 after 48-hours treatment was equal to 2.7 ± 0.2 mg/ml, while with ORNs treatment, IC50 was in the range of 6.9 ± 0.4 mg/ml. For the U251 cell line, a similar trend in viability after treatment was found, with IC50 for ORNs-D-m – 1.2 ± 0.04 mg/ml, for ORNs - 10.1 ± 0.2 mg/ml. For comparison, salt forms either showed no inhibitory effect on B16 or influenced at significantly higher concentrations compared to acid forms on U251.
Conclusions. ORNs-D-m inhibits the viability of B16 and U251 tumor cell lines. ORNs have a less inhibitory effect on viability. The acid form of ORNs-D-m has a more apparent effect on cell viability compared to the salt form.
